CardioComm Solutions, Inc.

CardioComm Solutions, Inc.

December 20, 2007 13:51 ET

CardioComm Solutions, Inc. Announces Sales, Marketing and Business Development Agreement for GlobalCardio 12 Lead

VICTORIA, BRITISH COLUMBIA--(Marketwire - Dec. 20, 2007) - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm" or the "Company") announces that it has signed a five year Sales, Marketing and Business Development Agreement with Strategic Healthcare Sales and Market Development LLC ("SHSMD") to lead the launch of GlobalCardio12 Lead.

The Agreement has SHSMD taking the lead in providing all of the sales, marketing and business development for GlobalCardio 12 Lead. The principals of SHSMD have over 25 years of experience in the healthcare sales and marketing field. The Company plans to formally launch and begin selling the product in January 2008, at a price that will be attractive in the market place, for technology that will revolutionize the way EKG services are managed. "It takes EKG into the 21st Century," said Jeff Mandler and Jim MacLeod, the two principals of SHSMD. The Agreement is subject to the approval of the TSX Venture Exchange.

Dr. Anatoly Langer, Chair of the Canadian Heart Research Centre and a member of the board, added, "We are very pleased with the engagement of SHSMD. Their experience in the North American sales of medical equipment will be of great asset to CardioComm as we enter this competitive but incredibly large clinical space. As a cardiologist, I am excited about GlobalCardio which enables web access and inexpensive delivery of the 12 lead EKG, the most commonly performed test in the work up of a patient with heart disease by physicians around the world."

In addition, the Company has negotiated outstanding debt of the Company in the amount of $63,450 to be settled in exchange for the issuance of an aggregate of 211,499 common shares of the Company to three persons. The shares will be issued at a deemed issue price of $0.30 per share. Consummation of the shares for debt transaction is subject to the approval of the TSX Venture Exchange.

About CardioComm Solutions, Inc.

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (EKGs), for diagnosis and management of cardiac patients. The Company's products are sold worldwide through a combination of its external distribution network and its North American based sales team. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time EKG viewer. CardioComm is the first company to provide a real-time means of viewing EKGs over a network (LAN, WAN or Internet). This tool enables EKGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global EKG Management System (GEMS™) and GlobalCardio™. CardioComm's software products have been cleared for sale in the United States by the U.S. Food and Drug Administration. The Company has earned the latest ISO 13485 certification.

On behalf of the Board of Directors of CardioComm Solutions, Inc.

Stephen R. Martin, President & CEO

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information